UKPAR Cefalexin 250 and 500 mg Capsules PL 35507/0104-5 5 responsible for pharmacovigilance and has the necessary means for the notification of any adverse reaction suspected of occurring either in the Community or in a third country.KPAR Cefalexin 250 and 500 mg Capsules PL 35507/0104-5 8 In-process controls have been provided and are appropriate considering the nature of the products and the method of manufacture. Process validation studies were conducted and the results were satisfactory.